COCP Cocrystal Pharma Inc

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal will present at the on Wednesday, April 22nd, 2020 at 11:00 AM ET.

A live of the presentation will be available on the page of the section of the Company’s website (). Immediately following the presentation, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live presentation and will be accessible for 30 days.



To schedule a one-on-one call with management, please contact the conference at and for more information, please visit .



About Virtual Investor Summit

The Virtual Investor Summit is an online platform that offers both public and private companies, across multiple industries the ability to stay active and engaged with the investment community. Our inaugural summit on April 22-23, 2020 will feature company webcast presentations followed by a virtual, interactive Q&A session, allowing participants to type in questions and receive live responses. Interested participants also have the ability to request one-on-one calls with a featured company. For more information, please visit .

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, noroviruses and coronaviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit .

Investor and Media Contact:

JTC Team, LLC

(833) 475-8247

EN
15/04/2020

Underlying

COCPCocrystal Pharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for N...

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact BOTHELL, Wash., April 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the f...

April 2, 2026 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates o...

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial result...

March 31, 2026 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating C...

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 09, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company...

March 9, 2026 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to ...

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Comp...

February 19, 2026 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Receives IRB Approval from Emory University School of...

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infectionThere are no approved treatments or vaccines currently available for norovirus infection BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) an...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch